This award recognition is positive for corporate reputation but has no direct financial or clinical implications. Traders should monitor upcoming Phase 2/3 trial readouts for VLS-01, EMP-01, or BPL-003 for material catalysts. The lack of financial or pipeline updates limits near-term trading relevance.
Price Chart
Executive Summary
AtaiBeckley Inc. received the Silver Award in OVID Health’s 2026 Patient Participant Index for its collaboration with the Psychedelic Participant Advocacy Network (PsyPAN) to integrate patient insights into clinical trial design and support. The recognition highlights the company's multiyear efforts to improve participant partnership in psychedelic research, including workshops, a peer-support pilot, and academic collaborations.
Key Facts
- AtaiBeckley received the Silver Award in OVID Health’s 2026 Patient Participant Index (PPI) in collaboration with PsyPAN.
- Recognition stems from a multiyear partnership focused on integrating clinical trial participant experiences into drug development.
- Initiatives included co-designed qualitative workshops, a public white paper, and a 12-month peer-support pilot program open to UK psychedelic trial participants.
- Collaboration has expanded to include King’s College London, University of Exeter, and international patient advocacy groups.
- No financial figures, revenue, or clinical trial results were disclosed in the release.
Financial Impact
No material financial impact disclosed
Risk Factors
- Press release contains no new clinical or financial data, limiting investor utility.
- Recent insider selling ($213K in past 30 days) contrasts with overwhelmingly bullish analyst consensus, suggesting potential divergence in sentiment.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281332 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 25-NSE | $7.30 awaiting T+20 | awaiting T+20 | — | — |
Aug 10, 2026 7w ago | DEFM14A | $7.25 $7.28 | ▲ +0.41% | ▲ +1.33% | — |
Aug 9, 2026 7w ago | Institutional Cluster | $7.25 $7.28 | ▲ +0.41% | ▲ +1.33% | — |
Jul 16, 2026 11w ago | DEFA14A / 8-K | $7.15 $7.25 | ▲ +1.40% | ▼ −2.22% | — |
Jul 7, 2026 12w ago | 144 | $5.17 $7.22 | ▲ +39.65% | ▲ +36.38% | — |
Jul 6, 2026 12w ago | Press Release | $4.96 $7.18 | ▲ +44.76% | ▲ +45.32% | — |
Jun 26, 2026 14w ago | 144 | $5.36 $7.18 | ▲ +33.96% | ▲ +34.23% | — |
Jun 25, 2026 14w ago | 144 | $5.29 $7.17 | ▲ +35.54% | ▲ +34.28% | — |
Jun 3, 2026 17w ago | 8-K | $4.53 $5.19 | ▲ +14.57% | ▲ +15.57% | — |
May 12, 2026 20w ago | Press Release | $4.15 $3.78 | ▼ −8.92% | ▼ −7.19% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access